These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 10722513)

  • 1. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
    Allen GP; Cha R; Rybak MJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro bactericidal activity of daptomycin against staphylococci.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
    Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of antibiotic susceptibilities and VISA-VRSA rates among MRSA strains isolated from hospitalized patients in intensive care units of hospitals in seven provinces of Turkey].
    Cesur S; Irmak H; Simşek H; Cöplü N; Kılıç H; Arslan U; Bayramoğlu G; Baysan BO; Gülay Z; Hoşoğlu S; Berktaş M; Gencer S; Demiröz AP; Esen B; Karabiber N; Aydın F; Yalçın AN
    Mikrobiyol Bul; 2012 Jul; 46(3):352-8. PubMed ID: 22951647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
    Mulazimoglu L; Drenning SD; Yu VL
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2428-30. PubMed ID: 8891159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.